infanrix-ipv+hib pdr for susp for injection
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - diphtheria toxoid, tetanus toxoid, bordetella pertussis, pertussis toxoid, filamentous haemagglutinin, fha, pertactin, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate - powder for suspension for injection - diphtheria toxoid 30 iu tetanus toxoid 40 iu bordetella pertussis 30 iu pertussis toxoid 25 µg filamentous haemagglutinin (fha) 25 µg pertactin 8 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg - vaccines
infanrix im suspension for injection
wael pharmacy - pt +fha+69k +dt +tt - suspension for injection
infanrix hexa powder and suspension for injection
wael pharmacy - dtpa-hbv-ipv/hib - powder and suspension for injection
infanrix hexa suspension for injection (im) (preservative-free)
glaxosmithkline philippines inc. - diphtheria, tetanus and pertussis (acellular component), hepatitis b (rdna), poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) (preservative-free)
infanrix hexa vaccine powder and suspension for suspension for injection 0.5ml pre-filled syringes
glaxosmithkline uk ltd - tetanus toxoid; pertussis antigens; human poliovirus type 3 inactivated; human poliovirus type 2 inactivated; human poliovirus type 1 inactivated; hepatitis b virus surface antigen; haemophilus influenzae type b polysaccharide protein conjugate; diphtheria toxoid - powder and suspension for suspension for injection
infanrix hexa suspension for injection (i.m.)
glaxosmithkline philippines, inc. - combined diphtheria, tetanus and acellular pertussis, hepatitis b, inactivated poliomyelitis and haemophilus influenzae type b vaccine (preservative-free) - suspension for injection (i.m.)
neisvac-c suspension for injection
baxter healthcare limited - neisseria meningitidis c tetanus toxoid - suspension for injection
boostrix 0.5 ml injection pre-filled syringe
glaxosmithkline australia pty ltd - pertussis toxoid, quantity: 16 microgram/ml; pertussis filamentous haemagglutinin, quantity: 16 microgram/ml; pertactin, quantity: 5 microgram/ml; diphtheria toxoid, quantity: 4 iu/ml; tetanus toxoid, quantity: 40 iu/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium phosphate; sodium chloride; water for injections - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older (see section 4.2 dose and method of administration).,boostrix is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see section 4.2 dose and method of administration, section 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties).,the use of boostrix should be in accordance with official recommendations.
boostrix 0.5 ml injection vial
glaxosmithkline australia pty ltd - pertussis toxoid, quantity: 16 microgram/ml; tetanus toxoid, quantity: 40 iu/ml; diphtheria toxoid, quantity: 4 iu/ml; pertactin, quantity: 5 microgram/ml; pertussis filamentous haemagglutinin, quantity: 16 microgram/ml - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; aluminium phosphate; sodium chloride - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older (see section 4.2 dose and method of administration).,boostrix is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see section 4.2 dose and method of administration, section 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties).,the use of boostrix should be in accordance with official recommendations.
boostrix polio suspension for injection
glaxosmithkline pte ltd - diphtheria toxoid; filamentous hemagglutinin (fha); inactivated polio virus type 1; inactivated polio virus type 2; inactivated polio virus type 3; pertactin (prn); pertussis toxoid (pt); tetanus toxoid - injection, suspension - diphtheria toxoid 2.5 lf/ 0.5 ml - not less than 2 iu; filamentous hemagglutinin (fha) 8 mcg/0.5ml; inactivated polio virus type 1 40 du/0.5 ml; inactivated polio virus type 2 8 du/0.5 ml; inactivated polio virus type 3 32 du/0.5 ml; pertactin (prn) 2.5 mcg/0.5 ml; pertussis toxoid (pt) 8 mcg/0.5 ml; tetanus toxoid 5.0 lf/0.5ml - not less than 20 iu